, is moving from the National Cancer Institute's Center for Cancer Research to Memorial Sloan-Kettering Cancer Center in New York City starting May 1, 2014. Dr. Landgren will serve as Attending Physician and Chief of the Myeloma Service, Division of Hematologic Oncology and as a Member, Memorial Hospital. He will also be proposed to a parallel academic appointment as Professor of Medicine at the Weill Cornell Medical College. Dr. Landgren has been a key figure in myeloma research and care at the National Cancer Institute acting as Senior Investigator and Chief of the Multiple Myeloma Section, Lymphoid Malignancies Branch (formally, Metabolism Branch). Drs. Bob Wiltrout, PhD, Director, CCR and Lee Helman, MD, Scientific Director for Clinical Research had kind words for Dr. Landgren and his contribution at the NCI.
Dr. Landgren is an international leader in the myeloma field. He transferred to the Center for Cancer Research in February, 2009 from the Division of Cancer Epidemiology & Genetics (DCEG), where he had established a productive research program centered on the molecular epidemiology of Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance (MGUS). While at CCR, Dr. Landgren expanded his research effort to the bedside with the focus on developing targeted strategies to delay, prevent and cure these diseases. He has pioneered the field of advanced treatment and minimal residual disease monitoring in the setting of smoldering myeloma, with the mission to find a cure. Dr. Landgren developed, implemented and enrolled patients on 14 investigator-initiated phase I/II clinical trials focusing on early myeloma (MGUS and smoldering myeloma), as well as newly-diagnosed and relapsed myeloma. His dedication to his patients and his drive to provide them with better treatments has been strong and consistent and he has published 143 peer-reviewed papers in that time, including 11 as first author and 74 as senior author. He received NIH tenure in 2011. During his time at CCR, Dr. Landgren has been active across the CCR community, both in his many scientific collaborations and in his leadership roles, such as Chair of the Scientific Review Committee for the Medical Oncology Branch, member of the CCR Clinical Research Strategic Planning Committee, and the CCR Grand Rounds Planning Committee, and NCI Representative on the Myeloma Steering Committee, Hematologic Malignancies Program, CTEP, DCTD. We are very fortunate that Dr. Landgren will maintain his scientific collaborations with NCI and the NIH community. Please join us in congratulating him on this new opportunity and thanking him for his work and collegiality during his time at CCR.
To set up an appointment with Dr. Landgren at MSKCC, call 646-497-9062 or visit the web site at www.mskcc.org (starting date May 1, 2014). You can also follow Dr. Landgren on Twitter https://twitter.com/DrOlaLandgren and find his full profile in the Online Myeloma Specialist Directory .
about the author
Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of Myeloma Crowd by HealthTree and the HealthTree Foundation.